| Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu | |
| Senan, Suresh; Brade, Anthony M.; Wang, Luhua; Vansteenkiste, Johan F.; Dakhil, Shaker R.; Biesma, Bonne; Aguillo, Maite Martinez; Aerts, Joachim; Govindan, Ramaswamy; Rubio-Viqueira, Belen | |
| 2015 | |
| 会议名称 | JOURNAL OF CLINICAL ONCOLOGY |
| 会议日期 | 2015-05-20 |
| 收录类别 | CPCI-S |
| URL标识 | 查看原文 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6660773 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Senan, Suresh,Brade, Anthony M.,Wang, Luhua,et al. Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsqu[C]. 见:JOURNAL OF CLINICAL ONCOLOGY. 2015-05-20. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论